Mexico Liver Cancer Drug Market Size & Outlook, 2025-2030
Related Markets
Mexico liver cancer drug market highlights
- The Mexico liver cancer drug market generated a revenue of USD 20.9 million in 2024 and is expected to reach USD 64.9 million by 2030.
- The Mexico market is expected to grow at a CAGR of 20.8% from 2025 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapy in 2024.
- Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
Liver cancer drug market data book summary
| Market revenue in 2024 | USD 20.9 million |
| Market revenue in 2030 | USD 64.9 million |
| Growth rate | 20.8% (CAGR from 2025 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies |
| Key market players worldwide | Bayer AG, Bristol-Myers Squibb Co, Eisai Co Ltd, Merck KGaA, Exelixis Inc, Eli Lilly and Co, GlaxoSmithKline Consumer Healthcare (GSK CH India), Petros Pharmaceuticals Inc Ordinary Shares, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Lupin, Emcure Pharmaceuticals, 23andMe Holding Co Class A, Hims & Hers Health Inc Ordinary Shares - Class A |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.6% of the global liver cancer drug market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. liver cancer drug market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 64.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liver Cancer Drug Market Scope
Liver Cancer Drug Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Hims & Hers Health Inc Ordinary Shares - Class A | View profile | 1046 | 2269 Chestnut Street, Suite 523, San Francisco, CA, United States, 94123 | https://www.forhims.com |
| Emcure Pharmaceuticals | View profile | 10001+ | Pune, Maharashtra, India, Asia | https://www.emcure.com/ |
| Exelixis Inc | View profile | 1310 | 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 | https://www.exelixis.com |
| Petros Pharmaceuticals Inc Ordinary Shares | View profile | 21 | 1185 Avenue of the Americas, 3rd Floor, New York, NY, United States, 10036 | https://www.petrospharma.com |
| GlaxoSmithKline Consumer Healthcare (GSK CH India) | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | https://india-consumer.gsk.com/ |
| Eisai Co Ltd | View profile | 11076 | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan, 112-8088 | http://www.eisai.co.jp |
| 23andMe Holding Co Class A | View profile | 816 | 349 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 | https://www.23andme.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Lupin | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | https://www.lupin.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
Mexico liver cancer drug market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer drug market will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 64.11% in 2024. Horizon Databook has segmented the Mexico liver cancer drug market based on targeted therapy, immunotherapy, chemotherapy, other therapies covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Mexico liver cancer drug market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Mexico liver cancer drug market databook
-
Our clientele includes a mix of liver cancer drug market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico liver cancer drug market , including forecasts for subscribers. This country databook contains high-level insights into Mexico liver cancer drug market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Mexico liver cancer drugs market size, by therapy, 2018-2030 (US$M)
Mexico Liver Cancer Drug Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
